• Je něco špatně v tomto záznamu ?

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

M. Beksac, S. Iacobelli, L. Koster, J. Cornelissen, L. Griskevicius, NK. Rabin, AM. Stoppa, E. Meijer, JB. Mear, S. Zeerleder, J. Mayer, R. Fenk, N. Fegueux, P. Chevallier, E. Konirova, JA. Snowden, M. Engelhardt, K. Orchard, C. Hulin, N. Schaap,...

. 2023 ; 58 (8) : 916-923. [pub] 20230509

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016750
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 37160942
DOI 10.1038/s41409-023-01999-1
Knihovny.cz E-zdroje

Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014-2017) (training cohort); Mel200 (n = 5616; 2018-2019) or Mel140 (n = 1523; 2018-2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (n = 1752) having a PFS-12 of 91.7% and the highest risk group (n = 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016750
003      
CZ-PrNML
005      
20231026105559.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-023-01999-1 $2 doi
035    __
$a (PubMed)37160942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Beksac, Meral $u Ankara University, Ankara, Turkey. beksac@medicine.ankara.edu.tr $1 https://orcid.org/0000000317978657
245    13
$a An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT / $c M. Beksac, S. Iacobelli, L. Koster, J. Cornelissen, L. Griskevicius, NK. Rabin, AM. Stoppa, E. Meijer, JB. Mear, S. Zeerleder, J. Mayer, R. Fenk, N. Fegueux, P. Chevallier, E. Konirova, JA. Snowden, M. Engelhardt, K. Orchard, C. Hulin, N. Schaap, C. Sossa, A. Elmaagacli, DP. McLornan, PJ. Hayden, S. Schönland, I. Yakoub-Agha
520    9_
$a Early relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014-2017) (training cohort); Mel200 (n = 5616; 2018-2019) or Mel140 (n = 1523; 2018-2019) (validation cohorts). PFS-12 and the Cumulative Incidence of Relapse at 12 months were 84.1% and 14.7% (training Mel200), 87.2% and 11.6% (validation Mel200), and 80.3% and 16.9% (validation Mel140), respectively. The points in the risk score were: 0, 1,2 for ISS stages I, II, and III; Disease status: 0 (CR/VGPR); 1 (PR); 2 (SD/MR); 4 (Relapse/Progression); and 1 for Karnofsky ≤ 70. The distribution of scores: 0 (24%), 1 (33.9%), 2 (29.6 %), 3 (9.5%), and ≥4 (2.7%). The score separated PFS-12, with the lowest risk group (n = 1752) having a PFS-12 of 91.7% and the highest risk group (n = 195) 57.1%. This also applied in cytogenetically high-risk patients. If the pre-score baseline risks are 15% (standard risk) and 25% (high-risk), a score of ≥4 confers calculated risks of 38% and 54%, respectively. This novel EBMT ER score, therefore, allows for the identification of five discrete prognostic groups.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x terapie $7 D009101
650    _2
$a kohortové studie $7 D015331
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a příprava pacienta k transplantaci $7 D019172
650    _2
$a melfalan $7 D008558
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a autologní transplantace $7 D014182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Iacobelli, Simona $u University of Rome Tor Vergata, Rome, Italy
700    1_
$a Koster, Linda $u European Society for Blood and Marrow Transplantation Leiden Study Unit, Leiden, the Netherlands
700    1_
$a Cornelissen, Jan $u Erasmus University Medical Center-Daniel Den Hoed, Rotterdam, the Netherlands
700    1_
$a Griskevicius, Laimonas $u Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania
700    1_
$a Rabin, Neil K $u University College London Hospitals NHS Foundation Trust, London, UK
700    1_
$a Stoppa, Anne Marie $u Institute Paoli-Calmettes, Marseille, France
700    1_
$a Meijer, Ellen $u VU University Medical Center, Amsterdam, the Netherlands
700    1_
$a Mear, Jean-Baptiste $u Centre Hospitalier Universitaire de Rennes, Rennes, France
700    1_
$a Zeerleder, Sacha $u University Hospital of Bern, Bern, Switzerland
700    1_
$a Mayer, Jiri $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Fenk, Roland $u University Hospital Duesseldorf, Dusseldorf, Germany
700    1_
$a Fegueux, Nathalie $u CHU Lapeyronie, Montpellier, France
700    1_
$a Chevallier, Patrice $u CHU Nantes, Nantes, France $1 https://orcid.org/0000000331425581
700    1_
$a Konirova, Eva $u Charles University, Prague, Czech Republic
700    1_
$a Snowden, John A $u Sheffield Teaching Hospitals NHS Trust, Sheffield, UK $1 https://orcid.org/0000000168193476
700    1_
$a Engelhardt, Monika $u University Medical Center Freiburg, Freiburg, Germany $1 https://orcid.org/0000000304051676 $7 xx0212540
700    1_
$a Orchard, Kim $u University Hospital Southampton NHS Foundation Trust, Southampton, UK
700    1_
$a Hulin, Cyrille $u CHU Bordeaux, Pessac, France
700    1_
$a Schaap, Nicolaas $u Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
700    1_
$a Sossa, Claudia $u Clinica FOSCAL, Floridablanca, Santander, Colombia $u Universidad Autónoma de Bucaramanga - UNAB, Bucaramanga, Santander, Colombia
700    1_
$a Elmaagacli, Ahmet $u Asklepios Klinik St. Georg, Hamburg, Germany
700    1_
$a McLornan, Donal P $u Queen's University Belfast, Marseille, France $1 https://orcid.org/000000031224091X
700    1_
$a Hayden, Patrick J $u Department of Haematology, School of Medicine, Trinity College Dublin, Dublin, Ireland $1 https://orcid.org/0000000313744503
700    1_
$a Schönland, Stefan $u University of Heidelberg, Heidelberg, Germany $1 https://orcid.org/0000000248535579
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ Lille, Infinite, Lille, France $1 https://orcid.org/0000000345248782
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 58, č. 8 (2023), s. 916-923
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37160942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105553 $b ABA008
999    __
$a ok $b bmc $g 2000336 $s 1203112
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 58 $c 8 $d 916-923 $e 20230509 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20231013
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace